Aspirin for the Prevention of Recurrent Venous Thromboembolism: The INSPIRE Collaboration.

Résumé

Auteurs » Simes J, Becattini C, Agnelli G, Eikelboom JW, Kirby AC, Mister R -More

Catégorie » Systematic review

Journal»Circulation

Year » 2014

Liens » Pubmed, DOI

Cet article est inclus dans 1 Structured summary of systematic reviews 2 Structured summaries of systematic reviews (1 reference) 2 Broad syntheses 2 Broad syntheses (2 references)

Cet article inclut 2 Primary studies 2 Primary studies (2 references)

This article is part of the following matrixes of evidence:

Extended antithrombotic treatment versus non-extended (placebo/no intervention) for the secondary prevention of venous thromboembolism
Aspirin versus no treatment for the secondary prevention of thromboembolic disease

Loading references information

BACKGROUND:

In patients with a first unprovoked venous thromboembolism (VTE) the risk of recurrent VTE remains high after anticoagulant treatment is discontinued. The Aspirin for the Prevention of Recurrent Venous Thromboembolism (the Warfarin and Aspirin [WARFASA]) and the Aspirin to Prevent Recurrent Venous Thromboembolism (ASPIRE) trials showed that aspirin reduces this risk, but they were not individually powered to detect treatment effects for particular outcomes or subgroups.

METHODS AND RESULTS:

An individual patient data analysis of these trials was planned, before their results were known, to assess the effect of aspirin versus placebo on recurrent VTE, major vascular events (recurrent VTE, myocardial infarction, stroke, and cardiovascular disease death) and bleeding, overall and within predefined subgroups. The primary analysis, for VTE, was by intention to treat using time-to-event data. Of 1224 patients, 193 had recurrent VTE over 30.4 months' median follow-up. Aspirin reduced recurrent VTE (7.5%/yr versus 5.1%/yr; hazard ratio [HR], 0.68; 95% confidence interval [CI], 0.51-0.90; P=0.008), including both deep-vein thrombosis (HR, 0.66; 95% CI, 0.47-0.92; P=0.01) and pulmonary embolism (HR, 0.66; 95% CI, 0.41-1.06; P=0.08). Aspirin reduced major vascular events (8.7%/yr versus 5.7%/yr; HR, 0.66; 95% CI, 0.50-0.86; P=0.002). The major bleeding rate was low (0.4%/yr for placebo and 0.5%/yr for aspirin). After adjustment for treatment adherence, recurrent VTE was reduced by 42% (HR, 0.58; 95% CI, 0.40-0.85; P=0.005). Prespecified subgroup analyses indicate similar relative, but larger absolute, risk reductions in men and older patients.

CONCLUSIONS:

Aspirin after anticoagulant treatment reduces the overall risk of recurrence by more than a third in a broad cross-section of patients with a first unprovoked VTE, without significantly increasing the risk of bleeding.